A lecture by Dr/ Ahmad Nofal about immunotherapeutic modalities in the treatment of warts

2. By
M.D

3. Introduction
 Destructive modalities
 Immunotherapeutic modalities
 Why CMI and IAI

7. IAI seems to enhance recognition of the
virus by the immune system. This in turn
allows clearance of both treated and
untreated lesions and helps to prevent
future clinical infection through induction
of a long-term acquired immunity to HPV,
leading to a prominent decrease in the
recurrence rates

8. Candidates: Healthy Immune subjects
Indications: different types of warts
Exclusion criteria:
patients with prior allergic response to the
injected antigen, acute febrile illness, past
medical history of asthma or allergic skin
disorders, pregnancy, lactation, and
iatrogenic or primary immunosuppression

9.  Procedure
 pre-sensitization
 Quantity
 Number of warts injected
 number of sessions
 Antigens
 Success Rates
 Time for Complete Response

11. Therapeutic Response & Clinical Variables

15. Adverse effects

16. Advantages
1-Low cost
2-Simple easy application
3-promising efficacy
4-Widspread efficacy
5-Low recurrence rates
6-High Safety profile
7-Absence of destructive adverse effects

17. 1-Numbers of the available studies are few
2-Absence of standardization
3-Restriction of candidates to healthy
subjects
4-Pain associated with injection
Disadvantages

18. Current Place

19. Future prospects

25. BCG Paste =3 Gm Salicylic + 3ml glycerin + I ml BCG